Health
Manochakian Calls for Repeat Genomic Testing Upon Osimertinib Progression in EGFR+ NSCLC – OncLive
Rami Manochakian, MD, discusses the role of osimertinib in patients with EGFR-mutated NSCLC, strategies for treatment following progression on the third-generation…
Because no standard approaches exist for patients with EGFR-mutated nonsmall cell lung cancer (NSCLC) who progress on standard frontline osimertinib (Tagrisso), repeat genomic testing should be done to identify potential resistance mechanisms that can help guide the next step in the treatment journey, Rami Manochakian, MD.
This is a very hot topic now. There are some potential rare, resistant mechanisms that could be a secondary actionable mutation such as MET amplification where you can potentially…
-
Noosa News18 hours agoNRL grand final quick hits: Reece Walsh creates magic after avoiding sin bin as Broncos survive Hunt, Reynolds injuries to win premiership
-
General18 hours agoHow the internet reacted to Brisbane Broncos winning the NRL grand final
-
Noosa News10 hours agoNew playground equipment encourages children to learn through ‘risky play’
-
General7 hours agoThree youths in police custody after fire at Ashley Youth Detention Centre in northern Tasmania